Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

I don't understand, your timeline matches up perfectly with what I was suggesting. Sunrise fully enrolled December 2015 (hopefully) and 2nd interim analyses which will halt the trial one year later. I expect the 2nd interim analysis in SUNRISE to occur in Nov/Dec 2016 and successfully reaching the OS endpoint will halt the trial...right on track with the company's guidance.

The Sorafenib trial was almost identical in terms of size and life expectancy so it's an estimate. Do you have a better example?

So the question remains, how does the company plan on funding itself until November 2016 when it prepares to file for approval in early 2017?